CAMBRIDGE, Mass., June 21,
2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
(Nasdaq: NRSN) ("NeuroSense"), a company developing novel
treatments for severe neurodegenerative diseases, announces
that it has received a notice of delisting from Nasdaq.
The staff of the Listing Qualifications Department has
determined that the Company's securities have not regained
compliance with the minimum $2,500,000 stockholders' equity requirement for
continued listing on The Nasdaq Capital Market, as set forth in
Listing Rule 5550(b). The Notice further states that unless the
Company timely requests a hearing before a Nasdaq Hearings Panel,
the Company's securities would be subject to delisting.
Accordingly, the Company intends to timely request a hearing
before the Panel. The hearing request will automatically stay any
suspension or delisting action pending the hearing. Pursuant to the
Nasdaq Listing Rules, the Panel has the discretion to grant the
Company an additional extension not to exceed December 18, 2024. At the hearing, the
Company will present its plan for regaining and sustaining
compliance with the Equity Requirement for continued listing.
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology
company focused on discovering and developing treatments for
patients suffering from debilitating neurodegenerative diseases.
NeuroSense believes that these diseases, which
include amyotrophic lateral sclerosis (ALS), Alzheimer's
disease and Parkinson's disease, among others, represent one of the
most signifiDcant unmet medical needs of our time, with limited
effective therapeutic options available for patients to date. Due
to the complexity of neurodegenerative diseases and based on strong
scientific research on a large panel of related biomarkers,
NeuroSense's strategy is to develop combined therapies targeting
multiple pathways associated with these diseases.
Forward-Looking Statements
This press release contains "forward-looking statements" that
are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as "anticipate," "believe," "contemplate," "could,"
"estimate," "expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Further, certain forward-looking statements are based
on assumptions as to future events that may not prove to be
accurate. The future events and trends may not occur and actual
results could differ materially and adversely from those
anticipated or implied in the forward looking statements. These
risks include unexpected R&D costs or operating expenses, a
delay in the reporting of additional results from PARADIGM clinical
trial, the timing of expected regulatory and business
milestones, risks associated with meeting with the FDA to determine
the best path forward following the results from PARADIGM clinical
trial, including a delay in any such meeting; the potential for
PrimeC to safely and effectively target ALS; preclinical and
clinical data for PrimeC; the uncertainty regarding outcomes and
the timing of current and future clinical trials; timing for
reporting data; the development and commercial potential of any
product candidates of Neurosense; and other risks and uncertainties
set forth in NeuroSense's filings with the Securities and Exchange
Commission (SEC). You should not rely on these statements as
representing our views in the future. More information about the
risks and uncertainties affecting NeuroSense is contained under the
heading "Risk Factors" in the Annual Report on Form 20-F filed with
the Securities and Exchange Commission on April 4, 2024 and NeuroSense's subsequent filings
with the SEC. Forward-looking statements contained in this
announcement are made as of this date, and NeuroSense undertakes no
duty to update such information except as required under applicable
law.
Logo -
https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/neurosense-receives-delisting-notice-from-nasdaq-and-intends-to-appeal-302179372.html
SOURCE NeuroSense